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Abstract
Epithelioid glioblastoma (E-GBM) is a rare aggressive variant of IDH-wildtype
glioblastoma newly recognized in the 2016 World Health Organization classiﬁcation,
composed predominantly of monotonous, patternless sheets of round cells with laterally
positioned nuclei and plump eosinophilic cytoplasm. Approximately 50% of E-GBM
harbor BRAF V600E, which is much less frequently found in other types of
glioblastomas. Most E-GBM are recognized as primary/de novo lesions; however, several
E-GBM with co- or pre-existing lower-grade lesions have been reported. To better
understand associations between E-GBM and the lower-grade lesions, we undertook a
histological and molecular analysis of 14 E-GBM, 10 of which exhibited lower-grade
glioma-like components (8 E-GBM with co-existing diffuse glioma-like components, 1
E-GBM with a co-existing PXA-like component and 1 E-GBM with a pre-existing PXA).
Molecular results demonstrated that the prevalence of BRAF V600E, TERT promoter
mutations and CDKN2A/B homozygous deletions in E-GBM were 13/14 (93%), 10/14
(71%) and 11/14 (79%), respectively, and concurrent BRAF V600E, TERT promoter
mutations and CDKN2A/B homozygous deletions were observed in 7/14 (50%) of E-
GBM. These alterations were also frequently seen in the lower-grade lesions irrespective
of the histology. Genetic analysis including array comparative genomic hybridization
performed for 5 E-GBM with co- and pre-existing lower-grade components revealed that
all molecular changes found in the lower-grade components were also observed in the E-
GBM components, and additional changes were detected in the E-GBM components. In
conclusion, E-GBM frequently exhibit BRAF V600E, TERT promoter mutations and
CDKN2A/B homozygous deletions and these alterations tend to coexist in E-GBM. Taken
together with the facts that only one PXA preceded E-GBM among these lower-grade
lesions, and that co-occurrence of BRAF V600E, TERT promoter mutations and CDKN2A/
B homozygous deletions have been reported to be rare in conventional lower-grade
diffuse gliomas, the diffuse glioma-like components may be distinct inﬁltrative
components of E-GBM, reﬂecting intratumoral heterogeneity.
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INTRODUCTION
Epithelioid glioblastoma (E-GBM) is a provisional uncommon var-
iant of IDH-wildtype glioblastoma newly recognized in the 2016
World Health Organization (WHO) classiﬁcation, characterized by
a relatively solid aggregate of monotonous round epithelioid cells
with abundant eosinophilic cytoplasm devoid of stellate processes,
some eccentrically positioned nuclei, conspicuous nucleoli and dis-
tinct cellular membranes (9). E-GBM tend to occur in young adults
and children, and the prognosis is particularly poor, even for glio-
blastomas, with an approximate median overall survival of 6
months (4, 9, 18, 19). From a genetic standpoint, approximately
half of E-GBM harbor BRAF V600E, which is much less fre-
quently found in other types of glioblastomas (9).
Although E-GBM are generally recognized as primary/de novo
lesions (9), several E-GBM with a pre- or co-existent lower-grade
components have been reported (1, 11, 18, 21, 22, 24, 28, 34, 35).
The fact that most of these lower-grade lesions documented so far
were pleomorphic xanthoastrocytomas (PXA) (1, 24, 34, 35) and
that both tumors commonly exhibit BRAF V600E supports the pos-
sibility that E-GBM and PXA are related; the association was rein-
forced by a recent study identifying heterozygous deletion of
ODZ3 (TEMN3) as a shared genetic alteration, found in 7 of 11 E-
GBM and 2 of 5 epithelioid PXA, deﬁned therein as tumors com-
posed predominantly of epithelioid cells with the same features as
seen in E-GBM, but also demonstrating at least a small component
of classic PXA (1). In addition, a few E-GBM with BRAF V600E
have been reported to accompany a low-grade diffuse glioma-like
component (11, 21, 22, 28).
In addition to BRAF V600E as a frequent genetic alteration in
PXA, homozygous 9p21.3 deletions involving CDKN2A/B have
been identiﬁed in 60%–83% of the cases (35, 38). Conversely,
only a small number of E-GBM has been shown to harbor the
homozygous deletions (1, 4, 28, 35), and the frequency in E-GBM
is not clear.
Recently, we reported a case of E-GBM with a diffuse
astrocytoma-like area demonstrating not only BRAF V600E but
also TERT promoter mutations in both histologically distinct com-
ponents (22); the prevalence of TERT promoter mutation in E-
GBM is also not known, and that in PXA and diffuse astrocytoma
has been reported to be 4 and 15%–32%, respectively (7, 8, 20).
In this report, we investigated 14 E-GBM, 10 of which exhibited
pre- or co-existing lower-grade (WHO grade II/III) glioma-like
lesions, and genetic associations between their E-GBM and lower-
grade components were explored by molecular and cytogenetic
analyses performed separately for each component, focusing on the
status of BRAF V600E, TERT promoter mutations, CDKN2A/B
deletions and ODZ3 deletions.
MATERIALS AND METHODS
Tumor samples
Fourteen cases of E-GBM were collected for this study (Table 1).
Six cases were previously reported (cases 2, 3, 5, 7, 8, 11) (11, 21,
22, 25, 28, 34). Five cases were from the consultation ﬁles of one
of the authors (S.N.). Two cases were from the pathology archives
of Department of Pathology, Gunma University Hospital. One case
was from the pathology archives of Japan Brain Tumor Reference
Center. Sections for histological and genetic analyses were pre-
pared from formalin-ﬁxed parafﬁn-embedded (FFPE) tissue speci-
mens. This study was conducted in accordance with the Gunma
University Ethical Committee.
Conventional histological analysis
Three-micrometer-thick tissue sections were cut and stained with
hematoxylin and eosin. Immunohistochemical staining was per-
formed on FFPE tissue sections. Primary antibodies directed
against the following antigens were applied: vimentin (V9; 1:200;
Dako, Glostrup, Denmark), glial ﬁbrillary acidic protein (GFAP;
1:5000) (27), Olig2 (1:5000) (40), cytokeratin (CAM5.2; 1:5; BD
Bioscience, San Jose, CA, USA), p53 protein (monoclonal, 1:50;
Leica Microsystems, Wetzlar, Germany), ATRX (polyclonal,
1:500; Sigma, St. Louis, MO, USA), BAF47/INI1 (BAF47; 1:100;
BD Bioscience, San Jose, CA, USA), BRG1 (polyclonal; 1:1000;
Millipore, Temecula, CA, USA) and Ki-67 (MIB-1; 1:100; Dako).
For coloration, a commercially available biotin-streptavidin immu-
noperoxidase kit (Histoﬁne, Nichirei, Tokyo, Japan) and diamino-
benzidine were employed.
For vimentin, GFAP, Olig2, p53 and CAM5.2 the intensity of
the staining was graded as negative, weak, moderate or strong and
the extent was scored as follows:2, totally negative; 11, <10% of
tumor cells are positive; 21, 10%–50% of tumor cells are positive;
31, >50% of tumor cells are positive.
DNA extraction
DNA was extracted from FFPE tissue sections, as previously
described (29). For E-GBM cases with a lower-grade area (cases 1,
3–10), the extraction was performed separately from an E-GBM
area and a lower-grade area.
Array comparative genomic hybridization
Array comparative genomic hybridization (CGH) analysis was car-
ried out using a 4 3 180 K CGH oligonucleotide microarray (Agi-
lent Technologies, Santa Clara, CA, USA), as described previously
(29). The sizes of gains and losses were reﬁned by manual inspec-
tion of probe intensity plots. The log2 ratio of <–1.0 at the region
of interest was considered to represent a homozygous deletion, and
a value of 21.0 to 20.2 was considered to represent a heterozy-
gous deletion (33).
Direct DNA sequencing for BRAF, IDH1/2,
H3F3A, TP53 and TERT promoter mutations
Genomic DNA extracted from FFPE sections was ampliﬁed and
sequenced using the primers described previously (2, 12, 26, 31,
36, 37). PCR products were sequenced on a 3130xl Genetic Ana-
lyzer (Applied Biosystems, Foster City, CA, USA) with the Big
Dye Terminator v.1.1 Cycle Sequencing Kit (Applied Biosystems)
following standard procedures.
Multiplex ligation-dependent probe
amplification analysis
Copy number changes in the CDKN2A/B genes, chromosomes 1
and 19 were analyzed by multiplex ligation-dependent probe ampli-
ﬁcation (MLPA) analysis. The SALSA MLPA probemix P088-C2
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(MRC-Holland, Amsterdam, the Netherlands) was used, and elec-
trophoresis data were analyzed using Gene Mapper software (Life
Technologies, Carlsbad, CA, USA) and normalized by Coffalyzer.-
net software (MRC-Holland). A dosage quotient (probe ratio) of
between 0.4 and 0.7 was taken to be indicative of a heterozygous
deletion, while a value< 0.4 was taken to represent a homozygous
deletion (16).
Fluorescence in situ hybridization analysis
Dual-probe hybridization using an intermittent microwave irradia-
tion method was applied to 4-lm-thick FFPE tissue sections, as
described previously (39). To investigate the copy number of
ODZ3, a 4q34.3–4q35.1 probe was prepared from a bacterial artiﬁ-
cial chromosome (BAC) clone, RP11–713O21, labeled with
ENZO Orange-dUTP (Abbott Molecular Inc., Des Plaines, IL,
USA) and a 4p15.1 probe was prepared from a BAC clone RP11–
81N11 labeled with ENZO Green-dUTP (Abbott Molecular Inc.).
Metaphase ﬂuorescence in situ hybridization (FISH) to verify clone
mapping positions was performed using the peripheral blood cell
cultures of a healthy donor.
RESULTS
Clinical data
Relevant clinical data are summarized in Table 1. Fourteen patients
were between 18 and 70 years of age, with half of them being less
than 30-year old. The female to male ratio was 10:4. All lesions
were supratentorial. Thirteen patients presented with a primary
lesion, and one patient had a previous history of PXA 13 years
prior to the onset (case 2) (34). All 14 patients underwent surgical
Table 1. Case list with clinical features.
Case Age (Yr)/Sex Location Histology Radiation, dose Chemotherapy Local
recurrence
Dissemination Extra
CNS
metastasis
Clinical
outcomes
1 21/M Temporo-parietal
lobe
E-GBM with
DA
Extended focal,
64.8 Gy
MCNU NA Yes Scalp Dead,
7months
28 12/F Temporal lobe PXA No No Yes No No –
(Rec) 25/F Temporal lobe E-GBM Extended focal,
60 Gy
TMZ NA Yes No Dead,
4.3 months
311 26/F Frontal lobe E-GBM with
DA
Extended focal,
60 Gy
TMZ No Yes Scalp Dead,
2 months
4 47/M Parietal lobe E-GBM with
AA
NA NA NA NA NA NA
59 22/M Occipital lobe E-GBM with
DA
Extended focal TMZ1IFN Yes Yes Vertebral
bodies,
lung thoracic
wall, liver
Alive at
24 months
6 32/M Parietal lobe E-GBM with
PXA
Extended focal,
67 Gy
TMZ No No No Alive at
10 months
710 18/M Temporal lobe E-GBM with
DA
Whole brain, 40
Gy
TMZ1IFN Yes Yes No Dead,
2 months
812 30/M Temporal lobe,
basal ganglia
E-GBM with
OA
Yes Yes NA NA NA Alive at
9 months
9 70/M Parietal lobe E-GBM with
DA
Extended focal,
40 Gy
TMZ Yes Yes No Dead,
7 months
10 23/M Frontal lobe E-GBM with
DA
Extended focal PCZ1ACNU
1VCR
Yes Yes Scalp Dead,
3 months
1117 18/M Temporal lobe E-GBM Extended focal ACNU1IFN Yes Yes No Dead,
0.7 months
12 32/F Occipital lobe E-GBM Extended focal,
60 Gy
TMZ No No No Alive at
26 months
13 47/M Parietal lobe E-GBM 1st: Extended
focal,
60 Gy
2nd: SRT
1st: TMZ1IFN,
2nd: IFM
1CDDP1VP16
Yes Yes No Dead,
25 months
14 65/F Frontal lobe E-GBM Extended focal,
60 Gy
TMZ NA NA NA Dead
Abbreviations: Yr5 years; M5male; F5 female; Rec5 recurrence; E-GBM5epithelioid glioblastoma; DA5 diffuse astrocytoma; PXA5 pleomor-
phic xanthoastrocytoma; AA5 anaplastic astrocytoma; OA5oligoastrocytoma; NA5 not avilable; MCNU5 ranimustine; TMZ5 temozolomide;
IFN5 interferon-beta; PCZ5 procarbazine; ACNU5nimustine; VCR5 vincristine; SRT5 stereotactic radiotherapy; IFM5 ifosfamide; CDDP
5 cisplatin; VP165etoposide.
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resection, and 12 of these cases with available clinical data received
subsequent chemoradiotherapy with temozolomide or other alkyl-
ating agents. Cerebrospinal ﬂuid dissemination and extra-CNS
metastasis were documented in ten and three cases, respectively. Of
14 cases, 10 had sufﬁcient clinical follow-up to evaluate outcomes.
Of these, seven patients (cases 1–3, 7, 9–11) died of disease within
7 months after the surgery due to the early tumor dissemination,
whereas three patients (cases 5, 12, 13) survived over 2 years with
or without local recurrence.
Histopathological findings
The histological features are summarized in Table 2 (Figure
1A–L). Nine of 14 E-GBM exibited co-existing lower-grade
Figure 1. Microscopic appearance. A–C. Epithelioid glioblastoma (E-
GBM) and diffuse astrocytoma (DA)-like components in case 9. The
interface between the E-GBM (top right) and DA-like (bottom left)
components is relatively sharp (A). Note the calcification in the DA-
like component (A,C). The E-GBM area is composed of monotonous,
discohesive round cells with laterally positioned nuclei and eosinophilic
cytoplasm (B). The DA-like component exhibits mild cellular prolifera-
tion of well-differentiated neoplastic fibrillary astrocytes (C). D. The
anaplastic astrocytoma-like component in case 4, presenting 4 mito-
ses per 10 high-power fields. E,F. The oligoastrocytoma-like compo-
nent with calcification (E) and osteoclast-like giant cells intermingled
with epithelioid tumor cells (F) in case 8. G. The PXA-like component
in case 6 shows a fascicular arrangement of spindle-shaped cells with
some multinucleated pleomorphic cells (inset). H,I. E-GBM (H) and its
precursor PXA lesion (I) in case 2. The PXA shows numerous eosino-
philic granular bodies (I). J. A component with anaplastic spindle-
shaped cells with monotonous nuclei and thick processes (case 12).
Frequent mitosis is seen (inset). K. Palisading necrosis in the E-GBM
component (case 10). L. Epithelioid tumor cells invade the vascular
wall in the subarachnoid space (case 6). The arrow indicates a tumor
cell right beneath the endothelium. Original magnification: A, x100; G,
I–K, x200; B–F, H, L inset in G and J, x400.
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components: E-GBM with a diffuse astrocytoma-like compo-
nent (cases 1, 3, 5, 7, 9, 10; Figure 1A–C), E-GBM with an
anaplastic astrocytoma-like component (case 4; Figure 1D),
E-GBM with an oligoastrocytoma-like component (case 8;
Figure 1E,F) or E-GBM with a PXA-like component (case 6;
Figure 1G). The interface between E-GBM and lower-grade
components was relatively sharp in cases 3, 5, 6, 8–10 (Figure
1A) and intraparenchymal and perivascular calciﬁcations
were frequently observed in these lower-grade areas (cases
1–4, 8–10; Figure 1A,C,E).
All E-GBM in this study were mainly composed of monotonous,
discohesive sheets of epithelioid cells with eosinophilic, rounded
cytoplasm lacking processes (Figure 1B,H). The nuclei were large,
laterally positioned, and variable in shape; round, ovoid, reniform
or crescent nuclei with distinct nucleoli were observed. The cyto-
plasm often contained ﬁlamentous-like or hyalinized inclusions
with or without ﬁne basophilic granules, and small cytoplasmic
vacuoles were also found in some tumor cells. Unlike conventional
GBMs, an interspersed ﬁbrillary matrix was not observed between
these tumor cells. Mitotic ﬁgures were frequent. In case 8, there
were numerous osteoclast-like giant cells intermingling with epithe-
lioid cells (Figure 1F) (11).
In diffuse astrocytoma-like components, a mildly cellular prolif-
eration of glial tumor cells with oval to irregular nuclei and cyto-
plasmic processes, in the background of a loosely structured matrix
were observed (cases 1, 3–5, 7, 9, 10; Figure 1C). Subpial and peri-
neuronal accumulation of tumor cells, indicating the inﬁltrative
nature of the tumor cells, were observed in some cases. Mitotic
ﬁgures were scant (case 7) or absent (cases 1, 3, 5, 9, 10). A lower-
grade component of case 4 showed similar histology but exhibited
4 mitotic ﬁgures per 10 high-power ﬁelds, meeting the criteria for
“anaplastic” astrocytoma (Figure 1D). In a oligoastrocytoma-like
component in case 8, ﬁbrillary astrocytic tumor cells and oligoden-
droglial tumor cells with a perinuclear halo were intimately mixed
(Figure 1E), where no mitotic ﬁgures were observed.
In case 6, a PXA-like component co-existing with E-GBM dem-
onstrated a fascicular arrangement of spindle-shaped cells with
some mononucleated or multinucleated pleomorphic cells (Figure
1G). Perivascular lymphocytic cufﬁngs and intercellular reticlin
meshwork were noted, although eosinophilic granular bodies
(EGBs) could not be identiﬁed. Mitotic ﬁgures were not observed.
The pre-existing PXA lesion in case 2 was composed of a com-
bination of spindle-shaped, xanthic and pleomorphic, multi-
nucleated giant astrocytes, with numerous EGBs, perivascular
lymphocytic cufﬁngs and abundant reticulin meshwork (Figure 1I).
In addition to the typical E-GBM areas, seven cases contained
another anaplastic area composed of spindle-shaped cells with rela-
tively monotonous nuclei and thick processes (cases 5, 7, 8, 10,
12–14; Figure 1J). Characteristics of localized astrocytomas (PXA
and pilocytic astrocytoma) as follows were not observed: piloid
cytoplasmic processes, xanthomatous change, Rosenthal ﬁbers or
EGBs. These areas were not regarded as lower-grade components
because of frequent mitosis, albeit less than in the E-GBM compo-
nents and necrosis seen in these components.
In areas of these epithelioid and anaplastic spindle-shaped cells,
coagulative necrosis was observed in all cases, whereas palisading
necrosis was identiﬁed in three cases (cases 10, 11, 13; Figure 1K),
and microvascular proliferation was absent in all cases. These
tumor cells tended to extend within the subarachnoid space, and in
most cases, characteristic vascular wall invasion (Figure 1L) and
intratumoral hemorrhage were observed.
The immunohistochemical ﬁndings are summarized in Table 2
(Figure 2A–L). E-GBM exhibited diffuse and strong staining with
vimentin (Figure 2A). GFAP immunoreactivity was identiﬁed in a
limited number of epithelioid cells with a few cytoplasmic proc-
esses (Figure 2B), but was diffusely observed in lower-grade gli-
oma cells (Figure 2C). Anaplastic spindle-shaped cells were
generally sparsely immunostained for GFAP (Figure 2D). Nuclear
Olig2 staining was variable in extent in epithelioid cells; mostly
negative in cases 5, 9, 11 and 13 (Figure 2E), whereas diffusely
positive in cases 12 and 14 (Figure 2F). Most E-GBM showed
weak to moderate p53 immunoreactivity (Figure 2G), but in cases
10 and 13, strong immunostaining was observed (Figure 2H).
CAM5.2 staining was focally observed in epithelioid cells in case
6–9, 12–14. The loss of ATRX nuclear expression was detected
only in case 4 (Figure 2I). The retention of nuclear staining of INI1
and BRG1 was observed throughout the specimen in all cases (Fig-
ure 2J). MIB-1 staining depicted markedly higher proliferation
indexes in the E-GBM components (Figure 2K) than those in the
lower-grade components (Figure 2L).
Genetic analysis
The results of genetic analysis are summarized in Table 2. The
prevalence of BRAF V600E, TERT promoter mutations and
CDKN2A/B homozygous deletions (Supporting Information Figure
S1A) detected by direct DNA sequencing or MLPA analysis in our
cohort of E-GBM were 13/14 (93%), 10/14 (71%) and 11/14
(79%), respectively. Concurrent BRAF V600E, TERT promoter
mutations and CDKN2A/B homozygous deletions were observed in
7 of 14 E-GBM (50%; cases 1, 3, 5–9). These 7 E-GBM were with
co-existing lower-grade lesions, of which ﬁve cases demonstrated
the same combination of alterations in their lower-grade lesions,
whereas none of these alterations were detected in the diffuse
astrocytoma-like area of case 3, and a CDKN2A/B homozygous
deletion could not be detected in the diffuse astrocytoma-like area
of case 9.
FISH analysis detected loss of heterozygosity (LOH) of ODZ3
in the E-GBM components of 2/14 cases (cases 2, 5), but not in
their lower-grade components (Supporting Information Figure
S1B).
The results of array CGH revealed that all copy number altera-
tions (CNA) observed in the lower-grade lesions were also
detected in the E-GBM components in all ﬁve cases analyzed
(Figure 3, Supporting Information Table S1). CNA recurrently
found only in the E-GBM components but not in the lower-grade
lesions were a gain on 3q24 - q26.2 (cases 1, 2), a heterozygous
deletion on 4q34.3 - q35.1 involving ODZ3 (cases 2, 5; Figure
3C), a heterozygous deletion on 6q11.1 - q22.33 (cases 2, 3), a
heterozygous deletion on 6q23.3 - q24.1 (cases 2, 3), a gain on
whole chromosome 7 (cases 1, 3) and a gain on 7q33 - q36.3
(cases 1–3). A homozygous deletion on 3q13.31 involving
LSAMP detected only in the E-GBM component of case 5, which
we previously reported (28), was not observed in any other cases.
Small homozygous deletions on 4q13.2 (cases 1, 5), 8p11.22
involving ADAM3A and ADAM5 (cases 3, 4), and 22q11.23
involving GSTT1 and GSTTP2 (cases 3, 5), and a small gain on
6p22.1 (cases 1, 4) recurrently found both in the E-GBM and
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lower-grade components were in regions of known benign copy
number variants (polymorphisms) reported in the Database of
Genomic Variants (DGV; http://dgv.tcag.ca/dgv/app/home). The
results of CNA involving CDKN2A/B and ODZ3 were compatible
with the results of MLPA and FISH analyses, respectively (Table
2, Figure 3, Supporting Information Figure S1). As for loss of
other important tumor suppressor genes, a heterozygous deletion
on 13q involving RB1 was found only in the E-GBM component
of case 2, a heterozygous deletion on 10q involving PTEN was
found both in the E-GBM and diffuse astrocytoma-like compo-
nents of case 1 and only in the E-GBM component of case 4, and
a heterozygous deletion on 17p involving TP53 was found only in
the E-GBM component of case 2 (Figure 3, Supporting Informa-
tion Figure S1).
No IDH1/2 or H3F3A mutation or 1p/19q loss was observed in
any cases analyzed (Supporting Information Figure S1A). TP53
mutations were found in two cases: a frameshift mutation
(c.633delT, pR213fs*34) only in the E-GBM component of case
10, and a silent mutation in codon 248 hot spot (c.742C>A,
p.R248R) in case 13, both of which are reported in the Catalogue
of Somatic Mutations in Cancer (COSMIC) database (http://cancer.
sanger.ac.uk/cosmic; Table 2).
Figure 2. Immunohistochemistry. A. Vimentin is diffusely and strongly
positive in E-GBM (case 9). B,C. A limited number of epithelioid cells
with a few cytoplasmic processes are positive for GFAP (B), and the
DA-like area is diffusely positive (C) in case 7. D. Anaplastic spindle-
shaped cells are sparsely immunostained with GFAP (case 5). E,F. The
extent and intensity of nuclear Olig2 staining is variable in the E-GBM
components; few and moderate in case 3 (E), whereas diffuse and
strong in case 12 (F). G,H. The E-GBM area has sparse and weak p53
immunoreactivity in case 3 (G), but diffuse and strong in case 13 (H). I.
The loss of ATRX nuclear expression in case 4 (E-GBM area). J. The
nuclear staining of INI1 is retained (E-GBM area of case 3). K,L. The
MIB-1 labeling index is approximately 60% in the E-GBM component
(K) and less than 1% in the DA-like component (L) in case 3. Original
magnification:A, C–L, x200; B, x400.
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DISCUSSION
Histologically and molecularly, PXA, particularly anaplastic PXA,
has been known to be related with E-GBM (9, 13). PXA and
E-GBM often share such features as a relatively solid growth pat-
tern, dural attachment and reticulin-rich areas, and it has been noted
that a subset of anaplastic PXA show similar histologic features to
Figure 3. Results of array comparative genomic hybridization (CGH).
A. Copy number alterations (CNA) detected by array CGH performed
separately for the E-GBM components and lower-grade lesions in
cases 1–5 are visualized. All CNA observed in the lower-grade lesions
were also detected in the E-GBM components in all cases. Homozy-
gous deletions involving CDKN2A/B were found both in the E-GBM
components and lower-grade lesions in cases 1, 2, 4 and 5, but only
in the E-GBM component in case 3. Several CNA were recurrently
found only in the E-GBM components, including a heterozygous dele-
tion on 4q34.3 - q35.1 involving ODZ3 (cases 2, 5). B. A homozygous
deletion involving CDKN2A/B in case 1. Chromosome 9 except the
deleted region demonstrated a low-level gain in the E-GBM compo-
nent. The positions of CDKN2A/B and a bacterial artificial chromo-
some clone RP11–149I2, which is commonly used for fluorescence in
situ hybridization analysis for investigating the copy number of
CDKN2A/B, are indicated. C. Heterozygous deletion involving ODZ3
observed only in the E-GBM components of cases 2 and 5. The posi-
tion of ODZ3 is indicated.
Abbreviations: E-GBM5 epithelioid glioblastoma; DA5 diffuse
astrocytoma-like component; PXA5pleomorphic xanthoastrocytoma.
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E-GBM, but E-GBM usually possess more cytologically uniform
cells and lack eosinophilic granular bodies unlike anaplastic PXA
(1, 17–19). From a genetic stand point, our results suggest that,
although BRAF mutations and CDKN2A/B homozygous deletions
are common in E-GBM and PXA, the frequency of TERT promoter
mutation is a deﬁnite difference between these tumors compared
with the reported frequency in PXA. Investigating 14 E-GBM, the
prevalence of BRAF V600E, TERT promoter mutations and
CDKN2A/B homozygous deletions in our cohort were 13/14
(93%), 10/14 (71%) and 11/14 (79%), respectively, and concurrent
BRAF V600E, TERT promoter mutations and CDKN2A/B homozy-
gous deletions were observed in 7/14 (50%) of E-GBM (Table 2).
BRAF mutations and CDKN2A/B homozygous deletions are com-
mon in PXA (50%–78% and 60%–83%, respectively) (14, 35, 38),
whereas, according to a single study, TERT promoter mutations
were found in 1/25 (4%) and 3/13 (23%) of PXA and anaplastic
PXA, respectively (20). It is of note that, although frequent BRAF
V600E, TERT promoter mutations and CDKN2A/B deletions have
not been reported so far in any other CNS tumor, this combination
of alterations was observed in a subset of melanomas (approxi-
mately 11%) (15), and morphological similarities between E-GBM
and melanomas have been pointed out (4, 18, 19).
Although most of the previously reported pre- or co-existent
lower-grade lesions with E-GBM have been PXA, 8 out of 10 in
our present cohort were diffuse gliomas: diffuse astrocytoma-like
components in six cases, an anaplastic astrocytoma-like component
in one case and an oligoastrocytoma-like component in one case.
BRAF V600E, TERT promoter mutations and CDKN2A/B homozy-
gous deletions were also frequently observed in these lower-grade
lesions; however, IDH1/2 mutations, genetic characteristics of
lower-grade diffuse gliomas, were not observed in any lesion
(Table 2). H3 K27M mutation has been reported in two cases of
E-GBM in the thalamus and spine, the former also harboring BRAF
V600E, but H3F3A K27M mutation was not detected in our pres-
ent cohort (1, 4).
In the current study, we compared the epithelioid cell and inﬁl-
trative lower-grade areas of E-GBM in regards to their histology,
and they were distinguished in terms of cytological features, growth
patterns (inﬁltrative or relatively solid), proliferative ability and
immunohistochemical ﬁndings (GFAP in particular). Calciﬁcation
was seen not only in a oligoastrocytoma-like area (case 8) but
also even in ﬁve diffusely inﬁltrating astrocytoma-like areas of 7
E-GBM cases (cases 1, 3, 4, 9, 10); calciﬁcation, a feature associ-
ated with slow growth, is a common histological ﬁnding in oligo-
dendroglial tumors, but is uncommon in diffuse astrocytomas (5).
Co-occurrence of BRAF V600E, TERT promoter mutations and
CDKN2A/B homozygous deletions are rare in diffuse gliomas.
Among 491 grades II–III diffuse gliomas in recent reports mostly
composed of adult cases (3, 6, 41), no cases shared BRAF V600E,
TERT promoter mutations and CDKN2A/B homozygous deletions.
As for glioblastomas (302 cases), seven cases had both BRAF and
TERT promoter mutations, of which three cases also had CDKN2A/
B homozygous deletions; however, epithelioid cell morphology
was not mentioned in these series. Meanwhile, concurrent BRAF
mutation and CDKN2A homozygous deletion have been found in a
subset of diffuse astrocytomas in children and young adults (10,
30). Mistry et al reported that BRAF mutations and CDKN2A dele-
tions (heterozygous or homozygous) constitute a clinically distinct
subtype of secondary high-grade gliomas (sHGG) transforming
from pediatric low-grade gliomas (PLGG) (23). These transforming
PLGG included “low-grade astrocytomas,” pilocytic astrocytomas,
PXA and gangliogliomas, and 2 of them (a low grade astrocytoma
and a ganglioglioma) had TERT promoter mutations in addition to
BRAF mutations and CDKN2A deletions; however, epithelioid cell
morphology was not mentioned in relation to sHGG (23). Together
with the fact that no E-GBM was preceded by a lower-grade diffuse
glioma in the current series, the lower-grade diffuse glioma-like
areas may be distinct inﬁltrative components of E-GBM, reﬂecting
intratumoral heterogeneity.
The exception is case 3, where BRAF V600E, TERT promoter
mutations and CDKN2A/B homozygous deletions were found in
the E-GBM component, but none of these alterations were detected
in the diffuse astrocytoma-like component. Moreover, although 2
CNA found in the diffuse astrocytoma-like component were also
detected in the E-GBM component using array CGH (Figure 3A,
Supporting Information Table S1), these CNA may be benign copy
number variants (polymorphisms); therefore, we could not detect
any possible somatic genetic changes in the diffuse astrocytoma-
like component, and could not reveal a genetic association between
these 2 components. Unrelated E-GBM and diffuse astrocytoma
may present as a collision tumor in this case; however, if not,
underlying more pathogenetically important alterations may be
shared both in these components, which could not be detected by
the methods used in this study.
In the current study, areas of anaplastic spindle-shaped cells with
relatively monotonous nuclei, a solid growth pattern, decreased
GFAP staining and devoid of characteristics of localized astrocyto-
mas (PXA and pilocytic astrocytoma) were found in 7 E-GBM
(Figure 2D, Table 2). This ﬁnding has not been featured in relation
to E-GBM, but can be a frequent element in E-GBM. Another his-
tological characteristic of E-GBM is tumor cell invasion into the
wall of vessels in the subarachnoid space, which was observed in
13 cases in the present study. This characteristic, together with the
discohesiveness of tumor cells, may be associated with the extra-
CNS metastasis, leptomeningeal dissemination and extensive intra-
tumoral hemorrhage (21, 28).
Case 4 is the ﬁrst E-GBM with loss of nuclear ATRX expression
ever reported (Figure 2I, Table 2). ATRX expression is almost
invariably lost in the setting of ATRX mutations, and the mutations
are frequently observed in IDH-mutant diffuse astrocytomas and
anaplastic astrocytomas (8). A small portion of E-GBM may
exhibit ATRX mutations mutually exclusively with TERT promoter
mutations as in diffuse gliomas (8).
For investigating the copy number of CDKN2A/B by FISH anal-
ysis, the BAC clone RP11–149I2 is commonly used; however, the
position of the BAC clone does not ﬁt into the homozygously
deleted regions in 3 of 5 E-GBM (cases 1, 4, 5) detected by array
CGH (Figure 3B, Supporting Information Table S1). We tested
FISH analysis using the BAC clone for the ﬁve cases analyzed by
array CGH, and validated the deletions in cases 2 and 3, but could
not in the cases 1, 4, 5 (data not shown). Deleted regions involving
CDKN2A/B in E-GBM may be narrower, as seen in other tumors
(32); therefore, other methods such as MLPA and array-based anal-
ysis may be suitable, the former being more appropriate for routine
use and screening large cohorts.
In conclusion, our results show that E-GBM frequently exhibit
BRAF V600E, TERT promoter mutations and CDKN2A/B homozy-
gous deletions, these alterations tend to coexist in E-GBM, and that
Nakajima et al BRAF, TERT and CDKN2A/B in E-GBM
Brain Pathology •• (2017) ••–••
VC 2017 International Society of Neuropathology
9
diffuse glioma-like components as well as PXA-like components
are commonly observed in E-GBM. Although PXA can rarely sec-
ondarily progress to E-GBM, the diffuse glioma-like components
may reﬂect intratumoral heterogeneity. Further studies with large
cohorts are needed to better understand the pathogenesis of E-
GBM.
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SUPPORTING INFORMATION
Additional Supporting Information may be found in the online
version of this article at the publisher’s web-site:
Table S1. Copy number abberations (CNA) detected by array
comparative genomic hybridization.
Figure S1. MLPA and FISH analysis. A. MLPA analysis shows
CDKN2A/B homozygous deletion (dosage quotient< 0.4) both
in oligoastrocytoma-like and E-GBM components of case 8.
IDH1/2 mutation or 1p/19q loss is not detected in either compo-
nent. B. LOH of ODZ3 is detected in recurrent E-GBM but not
in primary PXA of case 2, using a red probe targeting ODZ3
and a reference probe labeled in green. E-GBM; epithelioid
glioblastoma, PXA; pleomorphic xanthoastrocytoma, MLPA;
multiplex ligation-dependent probe ampliﬁcation, FISH; ﬂuores-
cence in situ hybridization, LOH; loss of heterozygosity.
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